Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis
ABSTRACT Amyotrophic lateral sclerosis (ALS) is a lethal disease affecting motoneurons. In familial ALS, patients bear mutations in the superoxide dismutase gene (SOD1). We transplanted human bone marrow mesenchymal stem cells (hMSCs) into the lumbar spinal cord of asymptomatic SOD1G93A mice, an experimental model of ALS. hMSCs were found in the spinal cord 10 weeks after, sometimes close to motoneurons and were rarely GFAP- or MAP2-positive. In females, where progression is slower than in males, astrogliosis and microglial activation were reduced and motoneuron counts with the optical fractionator were higher following transplantation. Motor tests (Rotarod, Paw Grip Endurance, neurological examination) were significantly improved in transplanted males. Therefore hMSCs are a good candidate for ALS cell therapy: they can survive and migrate after transplantation in the lumbar spinal cord, where they prevent astrogliosis and microglial activation and delay ALS-related decrease in the number of motoneurons, thus resulting in amelioration of the motor performance.
- SourceAvailable from: Masatoshi Suzuki[Show abstract] [Hide abstract]
ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the neuromuscular system and does not have a known singular cause. Genetic mutations, extracellular factors, non-neuronal support cells, and the immune system have all been shown to play varied roles in clinical and pathological disease progression. The therapeutic plasticity of mesenchymal stem cells (MSCs) may be well matched to this complex disease pathology, making MSCs strong candidates for cellular therapy in ALS. In this review, we summarize a variety of explored mechanisms by which MSCs play a role in ALS progression, including neuronal and non-neuronal cell replacement, trophic factor delivery, and modulation of the immune system. Currently relevant techniques for applying MSC therapy in ALS are discussed, focusing in particular on delivery route and cell source. We include examples from in vitro, preclinical, and clinical investigations to elucidate the remaining progress that must be made to understand and apply MSCs as a treatment for ALS.Stem Cell Research & Therapy 03/2014; 5(32). · 4.63 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Background aims Mesenchymal stromal cells (MSCs), after intraparenchymal, intrathecal and endovenous administration, have been previously tested for cell therapy in amyotrophic lateral sclerosis in the SOD1 (superoxide dismutase 1) mouse. However, every administration route has specific pros and cons. Methods We administrated human MSCs (hMSCs) in the cisterna lumbaris, which is easily accessible and could be used in outpatient surgery, in the SOD1 G93A mouse, at the earliest onset of symptoms. Control animals received saline injections. Motor behavior was checked starting from 2 months of age until the mice were killed. Animals were killed 2 weeks after transplantation; lumbar motoneurons were stereologically counted, astrocytes and microglia were analyzed and quantified after immunohistochemistry and cytokine expression was assayed by means of real-time polymerase chain reaction. Results We provide evidence that this route of administration can exert strongly positive effects. Motoneuron death and motor decay were delayed, astrogliosis was reduced and microglial activation was modulated. In addition, hMSC transplantation prevented the downregulation of the anti-inflammatory interleukin-10, as well as that of vascular endothelial growth factor observed in saline-treated transgenic mice compared with wild type, and resulted in a dramatic increase in the expression of the anti-inflammatory interleukin-13. Conclusions Our results suggest that hMSCs, when intracisternally administered, can exert their paracrine potential, influencing the inflammatory response of the host.Cytotherapy 08/2014; · 3.06 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Amyotrophic lateral sclerosis (ALS), characterized by the progressive loss of both upper and lower motor neurons, is a fatal neurodegenerative disorder. This disease is often accompanied by a tremendous physical and emotional burden not only for the patients, but also for their families and friends as well. There is no clinically relevant treatment available for ALS. To date, only one Food and Drug Administration (FDA)-approved drug, Riluzole, licensed 18 years ago, has been proven to marginally prolong patients' survival without improving the quality of their lives. Because of the lack of an effective drug treatment and the promising outcomes from several preclinical studies, researchers have highlighted this disease as a suitable candidate for stem cell therapy. This review article highlights the finding of key preclinical studies that present a rationale for the use of different types of stem cells for the treatment of ALS, and the most recent updates on the stem cell-based ALS clinical trials around the world.Neurology India 05/2014; 62(3):239-48. · 1.08 Impact Factor
Human mesenchymal stem cell transplantation extends survival, improves motor
performance and decreases neuroinflammation in mouse model of amyotrophic
A. Vercellia,b,⁎, O.M. Mereutaa,b, D. Garbossaa,b, G. Muracaa,b, K. Mareschib, D. Rustichellib, I. Ferrerob,
L. Mazzinic, E. Madonb, F. Fagiolib
aDepartment of Anatomy, Pharmacology and Forensic Medicine, National Institute of Neuroscience, Italy
bDepartment of Pediatrics, Regina Margherita Children's Hospital, University of Turin, Italy
cNeurologic Clinic, Ospedale Maggiore, Novara, Italy
a b s t r a c ta r t i c l ei n f o
Received 5 July 2007
Revised 5 May 2008
Accepted 22 May 2008
Available online 4 June 2008
Amyotrophic lateral sclerosis (ALS) is a lethal disease affecting motoneurons. In familial ALS, patients bear
mutations in the superoxide dismutase gene (SOD1). We transplanted human bone marrow mesenchymal
stem cells (hMSCs) into the lumbar spinal cord of asymptomatic SOD1G93Amice, an experimental model of
ALS. hMSCs were found in the spinal cord 10 weeks after, sometimes close to motoneurons and were rarely
GFAP- or MAP2-positive. In females, where progression is slower than in males, astrogliosis and microglial
activation were reduced and motoneuron counts with the optical fractionator were higher following
transplantation. Motor tests (Rotarod, Paw Grip Endurance, neurological examination) were significantly
improved in transplanted males. Therefore hMSCs are a good candidate for ALS cell therapy: they can survive
and migrate after transplantation in the lumbar spinal cord, where they prevent astrogliosis and microglial
activation and delay ALS-related decrease in the number of motoneurons, thus resulting in amelioration of
the motor performance.
© 2008 Elsevier Inc. All rights reserved.
Amyotrophic lateral sclerosis (ALS), Lou Gehrig's disease, is a
devastating degenerative disease involving motoneurons, affecting
around 2 people per 100,000 (Govoni et al., 2003). Motoneuron
degeneration leads to weakness, muscle atrophy, fasciculations,
spasticity (Rowland, 1998). Motoneuron degeneration arises from a
complex cascade involving crosstalk among motoneurons, glia and
muscles and evolving through the action of converging toxic
mechanisms (Strong, 2003). 5–10% cases are familial, and mutations
in anyof several geneshavebeen found inpatients (Wanget al., 2007).
One of these mutations involves the gene for Cu/Zn superoxide
dismutase 1 (SOD1, Rosen et al., 1993). Expression of ALS-associated
human SOD1 mutations (e.g. SOD1G93A) in mice produces a dom-
inantly inheritedsyndromewithclinical andhistopathologicalaspects
of ALS (Doble and Kennel, 2000; Selverstone Valentine et al., 2005).
Treatments that interfere with a specific event in the neurotoxic
cascade produce a modest increase in rodent lifespan, even though
multi-intervention approaches have recently been shown to be more
effective (Carri et al., 2006). Trophic factors such as insulin-like growth
factor (IGF-1, Nagano et al., 2005) and vascular endothelial growth
factor (VEGF, Storkebaum et al., 2005; Wang et al., 2007) can delay the
progression of the disease in ALS animal models. Stem cell transplanta-
in addition to pharmacological treatments (Mazzini et al., 2003, 2004;
cells could replace or protect motoneurons by releasing neurotrophic
mutation, whereas mutant protein-expressing cells can induce pathol-
ogy in wild type motoneurons (Clement et al., 2003). Human neural
stem cell grafts ameliorate motoneuron disease in SOD1 transgenic rats
(Xu et al., 2006). Moreover, whole bone marrow transplantation has
been shown to delay the disease onset and to increase lifespan in
SOD1G93Amice, and to participate instriatedmuscleregeneration (Corti
et al., 2004a,2004b, 2007). This stronglysuggests that the environment
of the dying neuron is crucial to its ability to function and survive.
We tested the effects of injecting human mesenchymal stem cells
(hMSCs) into the spinal cord on the progression of ALS in SOD1G93A
mice. We previously reported that hMSCs in culture can express
neural markers and neural ion channels, and produce trophic factors
(Mareschi et al., 2006). MSCs show unique immunologic properties for
cellular therapy: they are not immunogenic, do not stimulate
alloreactivity and escape lysis by cytotoxic T-cells and natural killer
Neurobiology of Disease 31 (2008) 395–405
⁎ Corresponding author. Dipartimento di Anatomia, Farmacologia e Medicina Legale,
corso M. D'Azeglio 52, 10126 Torino, Italy. Fax: +39 011 2367700.
E-mail address: email@example.com (A. Vercelli).
Available online on ScienceDirect (www.sciencedirect.com).
0969-9961/$ – see front matter © 2008 Elsevier Inc. All rights reserved.
Contents lists available at ScienceDirect
Neurobiology of Disease
journal homepage: www.elsevier.com/locate/ynbdi
(NK)-cells (Di Nicola et al., 2002; Le Blanc, 2003; Aggarwal and
Pittenger, 2005). Furthermore, Mazzini et al. (2003, 2006) reported a
good tolerance and a possible beneficial effect of injected autologous
hMSCs after expansion in vitro into the surgically exposed spinal cord
at T7–T9 levels in a few well-monitored ALS patients.
Materials and methods
Preparation of human mesenchymal stem cells
hMSC isolation and expansion
Bone marrow (BM) was obtained by aspiration from the posterior
iliac crest of healthy donors after informed consensus. BM cells were
layered over a 1.073 g/ml Percoll gradient (Sigma, St. Louis, MO, USA)
according to a previously reported method (Mareschi et al., 2001).
Briefly, the cells in the interface were collected, washed twice in the
0.1 M phosphate-buffered saline (PBS; pH 7.4), plated in MSC
medium (Cambrex Bio Science, Walkersville, MD, USA) at 8×105
cells/cm2in T flasks and maintained at 37 °C in an atmosphere of 5%
CO2. After 3 days the non-adherent cells were removed and replaced
with fresh culture medium. Subsequent complete medium changes
were performed every 4 days. After 15 days for the first passage and
every week for the following passages, BM cells were detached by
treatment with 0.25% trypsin containing 0.01% EDTA for 10 min at
37 °C. They were plated at a density of 8000/cm2and expanded for
several passages up to prevent the confluence. The cells were
analysed for their viability and for their immunophenotype by flow
Characterization of hMSCs
The flow cytometry analysis of adherent hMSCs was performed at
each passage. 200,000–500,000 cells were incubated for 20 min with
anti-CD45FITC/CD14PE, CD90FITC/CD106PE, CD29FITC/CD44PE,
CD166FITC/CD105PE antibodies for the identification of the immuno-
phenotype and with 7-aminoactinomycin D (7-AAD; Becton Dick-
inson, San Jose, CA, USA) for their viability. Labelled cells were
thoroughly washed with PBS 1× (Cambrex Bio Science, Verviers,
Belgium) and analysed on an Epics XL cytometer (Beckman Coulter,
CA, USA) with the XL2 software program. The percentage of positive
cells was determined based on the fluorescent emission of the
nonspecific FITC/PE isotypic antibody controls. The cells which were
negative for CD45 and CD14 and positive for the other markers were
Prelabelling of hMSCs
Cells expanded for the first 3–8 passages were labelled by adding
to the medium 10 μg/ml bisbenzimide (Sigma, St. Louis, MO, USA),
which binds to DNA, 24 h before transplantation. Then the cells were
detached with Trypsin/EDTA, washed and resuspended in saline
solution to obtain a final concentration of 50,000 cells/μl to be used for
Transgenic B6SJL-TgN(SOD1-G93A)dl1Gur/J mice overexpressing
human SOD1 carrying the Gly93 to Ala mutation (G93A) were used in
this study. The breeding pairs were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA) and the transgenic mice were
genotyped using a described polymerase chain reaction (PCR) method
(Rosen et al.,1993). These mice develop initial signs of neuromuscular
deficits at 34.4±3.4 weeks and die at 37.9±3.0 weeks of age. Beginning
at 34 weeks of age, food and water were routinely placed in the cages
in order to get easy access. All procedures involving the use of live
animals were performed under the supervision of a licensed
veterinarian, according to the guidelines specified by the Italian
Ministry of Health (DDL 116/92).
A series of SOD1G93Amice were used for pilot studies in order to
understandthebest site of injection,thediffusion of transplanted cells
into the host and their potential for differentiation into neural cells.
We decided to use SOD1G93Aand not wild type mice since we wanted
to test these issues directly in pathological mice, hypothesizing that
the pathological brain can stimulate and attract hMSCs.
hMSCs (105cells) were transplanted in the lumbar spinal cord of the
SOD1G93Amice aged 28 weeks, before ALS symptoms became manifest.
The lumbar region was chosen for transplantation due to its early
involvement in this ALS model. In a separate set of experiments hMSCs
space, but these sites of injection were abandoned since no transplanted
cells were found into the spinal cord after sacrifice at 38 weeks.
The study included SOD1G93Amice transplanted with hMSCs
(n=25) and sham-operated transgenic mice (n=12). We also con-
sidered the sex of the mice (n=19 males and n=18 females), since it
has been reported that the progression has a different time course in
the two sexes (Suzuki et al., 2007).
Underchloral hydrateanesthesia(250 mg/kg body weightof a 0.3%
solution in saline), the lumbar spinal cord was exposed through a
laminectomy 2 cm under the intersection of the line connecting the
inferior angles of the scapulae with the vertebral column. 2 μl of hMSC
suspension (transplanted animals) or saline (sham-operated animals)
was gently injected into the L1–L2 neuromers, using a glass
micropipette (outer diameter=30 μm) connected to a syringe body
by a silicon tube.
This surgical procedure was set up before transplantation in adult
mice by injecting at different levels the fluorescent tracer 1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI,
5% dissolved in dimethylformamide; Molecular Probes, Eugene, OR,
USA), and observing the location of the injection site in the spinal cord
at the fluorescent microscope after sacrifice (data not shown).
We decided to sacrifice the mice at the age of 38 weeks, the mean
age of death in transgenic mice. Animals were killed byan overdose of
anesthetics, perfused through the ascending aorta with saline
followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB; pH
7.3). Since several mice died before this age, those which were found
dying were killed immediately, whereas those found dead were
dissected and immersion fixed.
The lumbar spinal cord (between the end of T13 and the beginning
of L4, including the lumbar enlargement) was dissected and isolated,
immersed in the same fixative for 1 h, cryoprotected in 30% sucrose
solution in PB overnight and frozen in cryostat medium (Bio-Optica,
Milan, Italy). The tissue was cut in coronal 50 μm-thick serial sections.
Theywere mounted onto 1% gelatine-coatedslides, which were stored
at −20 °C until they were reacted forhistologyor immunofluorescence
Quantification of alpha motoneurons
Quantification was performed only in mice which survived
38 weeks and which showed surviving hMSCs into the lumbar spinal
cord. One series of serial lumbar sections (one every 600 μm) was
stained with cresyl violet. The nucleoli of the neurons in the ventral
horns of the spinal cord were counted at 40×, in a total number of 12
sections/mouse. Only neurons with an area ≥200 μm2, classified as
alpha motoneurons, were counted (Ciavarro et al., 2003). A total
estimated number of alpha motoneurons was obtained with a
stereological technique, the Optical Fractionator (West et al., 1991),
by using a computer-assisted microscope and the StereoInvestigator
software (MicroBrightField, Williston, VT, USA). Cells were counted on
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405
the computer screen using an Optronics MicroFire digital camera
mounted on a Nikon Eclipse E600 microscope.
Briefly, the Optical Fractionator is a stereological method for
obtainingestimates of the total number of neurons. It is a combination
of a three-dimensional probe for counting neuronal nuclei, the Optical
Dissector, and a systematic uniform sampling scheme, the Fractio-
nator. To determine the number of alpha motoneurons, we used a
modified version of the fractionator principle. The rationale for this
modification lies in the fact that the alpha motoneurons are not evenly
distributed in the ventral horn of the spinal cord. When an automated
stereology system, such as StereoInvestigator, is used, this leads to a
high number of counting frames, most of which do not contain alpha
motoneurons. Only the cells in the uppermost focal plane were
excluded to avoid oversampling, but the alpha motoneurons were
otherwise counted exhaustively in the ventral horn of T13–L4 lumbar
segment. The total number of alpha motoneurons was then estimated
by multiplying the resulting counts by 12, because only every twelve
section had been used for counting. The numbers obtained in our
study are thus absolute numbers and are independent of the volume
of the spinal cord. The guard zones were of 5 μm and the scan grid size
was 240×160 μm, the optical dissector=mean section thickness, with
a Gundersen coefficient error ranging from 0.04 to 0.1.
Immunofluorescence labelling to analyse reactive astrogliosis
A series of sections (one every 600 μm) from 10 transplanted and 5
sham-operated females and from 8 transplanted males was incubated
for 20 min at room temperature (r.t.) with PBS containing 0.3% Triton X-
100 (Sigma, St. Louis, MO, USA) to increase membrane permeability.
After rinsing in PBS, sections were incubated in PBS-0.1% Triton X-100
with 10% normal donkey serum (NDS; Sigma, St. Louis, MO, USA) for
were incubated overnight at 4 °C in PBS-0.1% Triton X-100 with 50%
blocking solution and 1:500 rabbit anti-glial fibrillary acid protein
(GFAP; DAKO, Denmark). After rinsing in PBS, the primary antibodies
were detected using Cy3-conjugated donkey anti-rabbit IgG (H+L)
1:400 in PBS-0.1% Triton X-100 with 2% NDS for 1 h at r.t. Controls were
mounted in PBS-glycerol (1:1) and observed with a Nikon Eclipse E800
epifluorescence microscope under appropriate filter sets. GFAP immu-
noreactivity was analysed in one section every 1200 μm to evaluate
reactive astrogliosis. The ventral horns were photographed using a
Nikon Coolpix 995 digital camera at 40×, obtaining 24 photos for each
animal. The percentage of the total area which was GFAP-positive was
quantified using the Scion Image for Windows (freeware version of NIH
image, Scion Corporation, Frederick, MD, USA).
Immunohistochemistry for microglial antigen (CD11b)
In order to detect microglial activation, other sections from 4
transplanted and 4 sham-operated females and from 4 transplanted
males were incubated overnight at 4 °C with rat anti-mouse
polyclonal antibody CD11b (Serotec Ltd, Oxford, UK) diluted 1:100 in
PBS-0.1% Triton X-100 with 2% normal goat serum (NGS Sigma), and
2 h r.t. in 1:50 biotinylated anti-rat secondary antibody (Serotec Ltd)
followed by avidin–biotin–peroxidase complex (ABC) solution (Vec-
stain ABC Kits, Vectors Laboratories Inc., Burlingame, CA) and then
with peroxidase substrate kit Vector SG (Vectors Laboratories Inc.)
until staining was optimal as determined by light microscopic
examination. Labelled sections were washed in PBS and mounted
onto 1% gelatine-coated slides, air-dried overnight, dehydrated and
coverslipped with Eukitt (O Knidler GmbH and Co., Freiburg,
Germany). CD11b immunoreactivity was also quantified as above in
order to evaluate microglial activation.
In order to study the differentiative potential of hMSCs some
sections, in which bisbenzimide-labelled cells had been detected, were
immunoreacted against microtubule-associated protein 2 (MAP2, 1:10
monoclonal antibody AP18, a generous gift from Riederer BM, IBCM,
University of Lausanne, Switzerland) and GFAP, in search for double
(bisbenzimide and MAP2 or GFAP) labelled hMSCs. We counted the
number of MAP2 or GFAP-positive MSCs over a total number of four
hundred bisbenzimide-positive nuclei for each marker.
In order to analyse the effect of MSC transplantation on the onset
and progression of motor symptoms in this disease model, we
performed four clinical tests: i) scoring of motor deficits by a trained
observer, ii) weighing and iii) performance on the Rotarod task, all of
which are commonly used to evaluate SOD1G93Aanimals (Weydt et al.,
2003). In addition, we investigated the iv) Paw Grip Endurance (PaGE)
test which has the dual advantage of measuring motor strength
directly while requiring only minimal equipment (Weydt et al., 2003).
Beginning at 24 weeks, the animals (sham-operated — three males
and 5 females, and transplanted — 9 males and 10 females) were
assessed weekly with the behavioral tests in randomized order by an
observer blinded to the treatment. The first 3 weeks of tests were
considered as training.
The mice were evaluated for signs of motor deficit with the
following 4 point scoring system: 4 points if normal (no sign of motor
dysfunction); 3 points if hind limb tremors are evident when
suspended by the tail; 2 points if gait abnormalities are present; 1
point for dragging of at least one hind limb; 0 points for inability to
right itself within 30 s. Onset was defined retrospectively as the
earliest time when the mice showed symptoms (score b4) for ≥2
For the Rotarod test the time for which an animal could remain on
the rotating cylinder was measured in a 7650 accelerating model of a
Rotarod apparatus (Ugo Basile, Italy). Each animal was given three
trials and the longest latency to fall was recorded; 180 s was chosen as
the arbitrary cut-off time.
For the PaGE test each mouse was placed on the wire-lid of a
conventional housing cage. The lid was gently shaken to prompt the
mouse to hold onto the grid before the lid was swiftly turned upside
down. The latency until the mouse lets go of the grip with at least both
hind limbs was timed. Each mouse was given up to three attempts to
hold on to the inverted lid for an arbitrary cut-off time of 90 s and the
longest latency was recorded.
In motor tests some treated and control animals never achieved
respective cut-off times even though they behaved otherwise normal.
To eliminate this variability in maximal performance, all data were
normalized to the maximal value achieved by each mouse during the
whole period examined. Body weight was normalized tothe weight at
27 weeks. The animals were considered end-stage when they reached
a motor score of 0 points or lost N20% of their body weight, whichever
Data were given as mean±standard deviation or standard error of
mean and assessed by Student's t-test and ANOVA in order to compare
the values of motoneuron counts, reactive astrogliosis and microglial
activation obtained for the sham-operated and MSCs transplanted
females and males, respectively. pb0.05 was considered significant.
The cells isolated from bone marrow were hMSCs showing the
specific features defined by the International Society for Cellular
Therapy guidelines (Dominici et al., 2006). In fact, they were adherent
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405
cells positive for CD90, CD106, CD29, CD44, CD105, CD166 markers,
negative for the hemopoietic markers such as CD45 and CD14.
Moreover, these cells were able to differentiate in osteoblasts,
chondroblasts and adipocytes after exposure to specific conditioning
media as previously shown (Mareschi et al., 2001; Ferrero et al., 2008).
hMSC migration and expression of neural markers
When hMSCs were injected into the cisterna magna, or in the
spinal subarachnoideal space, no bisbenzimide-positive nuclei were
found within the spinal cord (Fig. 1). Some bisbenzimide-positive
nuclei were found on the surface of cerebral cortex, or on the pial
meninge, or, rarely, in the hippocampus. Therefore we decided to
consider only mice which were injected into the spinal cord.
MSCs were identified as cell aggregates distributed close to the
injection site, especially in the dorsal column and median posterior
commissure of white matter. Cells were also recognized in the ventral
horn of the lumbar spinal segment (degeneration area). Some of them
were found at a few microns from the motoneurons (Fig. 2). This
suggested that MSCs could migrate far from the injection site into the
subarachnoidal space and also along the dorsoventral axis of the
spinal cord. In some cases, cells migrated along the craniocaudal axis
of the spinal cord for a distance of 1550 μm from the injection site.
Rare (b1%) GFAP (Figs. 2A–C) or (b1%) MAP2 (Figs. 2D–F) bisbenzi-
mide-positive cells were found.
Motoneurons were clearly recognized for their large size, for their
difference in the number of motoneurons between transplanted and
sham-operated SOD1G93Amice was evident in histological sections and
difference (pb0.05) in their number between transplanted and sham
female SOD1G93Amice (Figs. 3A and B respectively). Sham-operated
female SOD1G93Amice at 38 weeks of age had 3549±607 (mean±
standard error, 4 mice) motoneurons, whereas female SOD1G93Amice
which had received a hMSC injection at 28 weeks displayed 5458±682
(mean±standard error, 7 mice) at 38 weeks of age. Unfortunately, no
sham-operated male SOD1G93Amice survived up to 38 weeks of age, and
only three transplanted male SOD1G93Amice survived to allow cell
counts, which gave 3766±980 motoneurons. Nevertheless, counts of
motoneurons in six sham-operated male SOD1G93Amice which died
between 35 and 37 weeks of age gave 1489±408 (pb0.05).
We investigated the effect of transplanted hMSCs on the microglial
activation. The immunohistochemistry for CD11b, a characteristic
marker of microglial cells, showed a reduced level of the activated
microglia in the treated mice (Figs. 4A–D). This was confirmed by the
quantitative analysis of the reaction in both transplanted and control
mice (one-way Student's t-test pb0.01) (Fig. 4G). In fact, whereas
sham-operated females had a 30.73±1.99 value, treated females had a
value of 19.612±0.251 and treated males 22.674±1.015.
GFAP-positive profiles are directly proportional to reactive astro-
cytes and the role that these cells may play in the pathogenesis of the
Fig.1. Localization of transplanted hMSCs. Bisbenzimide-stained nuclei in the lumbar spinal cord (A, B) following intraparenchimal injection and on cerebral cortex (C, D) following
injection in the cisterna magna. In A, injection site at small magnification. In C, transplanted hMSCs are located on the pial surface, whereas in D they enter the superficial cortical
layers. Scale bars=100 (A, B) and 50 (C, D) μm.
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405
Fig. 2. Expression of neural markers by transplanted hMSCs. Double stained cells for bisbenzimide and GFAP (A–C) and MAP2 (D–F) in transverse sections of lumbar spinal cord. In
G, H, localization of bisbenzimide-positive cells (blue) close to motoneurons (stained with MAP2 antibody, green). Scale bars=30 (A–F), 50 (G) and 20 (H) μm.
Fig. 3. Motoneurons in the lumbar spinal cord. Transverse sections of transplanted (A) and sham-operated (B) female SOD1G93Amice at 38 weeks of age. Motoneuron profiles are
clearly reduced in number in B compared to A. Scale bar=200 μm.
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405
Fig. 4. Quantification of microglial activation and of reactive astrogliosis. CD11b-immunohistochemistry at low (A, B) and high (C, D) magnification in hMSC transplanted (A and C)
and sham-operated (B and D) SOD1G93Amice. In E and F GFAP-immunofluorescence in hMSC transplanted (E) and sham-operated (F) SOD1G93Amice. Scale bars=200 (A, B) and
50 (C–F) μm. In G and H quantification of CD11b- and GFAP-positive profiles, respectively, in sham-operated females (dashed bar), hMSC transplanted females (empty bars) and
hMSC transplanted males (filled bars).
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405
disease. Reactive astrocytosis refers to the increase in number and the
hypertrophy of astrocytes expressing GFAP and is known to occur in
response to neural injuries. Using this quantitative parameter, we
investigated if the release of neurotrophic factors by the transplanted
MSCs could reduce the reactive astrogliosis (Figs. 4E, F).
We observed a significant reduction of the GFAP reactivity in the
transplanted females compared with the control ones (one-way
Student's t-test pb0.01). Because of the post-mortem degradation, it
was not possible to analyse the reactive astrocytosis for the sham-
operated males which died before 38 weeks of age. Anyway, we report
a higher percentage of reactive astrocytosis for the transplanted males
(2.52±0.79) compared tothe transplanted females (1.8±0.25) and also
a reduction of GFAP expression for the transplanted males compared
to sham-operated females (3.3±0.25). The statistical analysis includ-
ing the three groups of animals resulted significant (one-way
Student's t-test pb0.01) (Fig. 4H).
We evaluated the effects of the transplanted hMSCs on the
progression of behavioral deficits. The statistical analysis considered
the results obtained beginning with the 27th week of age. All data
the whole period examined since some treated and control animals
neverachieved respectivecut-off times (180 s for Rotarodtest and90 s
for PaGE test). Body weight was normalized to the weight at 27 weeks.
The first clinical signs of motor neuron disease in SOD1G93Amice
were fine hind limb tremors (Figs. 5A and B). The treated males began
to display hind limb tremors (motor score=3 points) around 32–
35 weeks of age and achieved a motor score of 1 or 2 points at the
sacrifice date (Fig. 5A). The control males (Fig. 5A) showed gait
abnormalities (motor score=2 points) starting already from 30 to
32 weeks. Two of them died spontaneously before 38 weeks of age
Fig. 5. Behavioral tests. Results obtained with neurologic (A, B), Rotarod (C, D) and PaGE (E, F) tests on male (A, C, E) and female (B, D, F) SOD1G93Amice, from 27 to 38 weeks of age.
Dashed line corresponds to sham-operated mice, whereas continuous line corresponds to hMSC transplanted mice. Bars are standard deviations. Data are expressed as motor score
for neurologic test, and as percentage of the performance at 27 weeks of age for Rotarod and PaGE tests.
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405
andtheotheronereacheda motor score of0 points at week 37. Almost
all of the transplanted females registered a motor score of 4 points
until 38 weeks of age, whereas the sham-operated females showed
signs of motor dysfunction (motor score=2 or 3 points) at the 37th
week of age (Fig. 5B). Regarding the weight loss characteristic for the
disease progression, no difference was observed in treated mice
compared to control ones (data not shown).
In the Rotarod task (Fig. 5D), the transplanted females sustained
their maximal performance level, whereas the performance of the
sham-operated females began to decline starting with the 35th week.
However, this difference was not statistically significant. The results
were similar for the PaGE test (Fig. 5F). No survival improvement was
described for treated females. On the contrary, the Rotarod
performance curve showed a different time course for treated and
control males. Around week 28 the performance of the sham-
operated males began to decline slowly and this difference became
significant at 32 weeks of age. The control males failed the test after
week 35 (Fig. 5C).
In the PaGE task, starting with the 34th week the transplanted
males showed a reduced performance of 60–70% whereas the control
ones failed the test(Fig. 5E). Treated males also displayed an improved
survival: 40% survived to 38 weeks, whereas all sham-operated males
died before that age.
Our study provides evidence that mesenchymal stem cells are a
good candidate for cell therapy in ALS: i) they can survive and migrate
after transplantation in the lumbar spinal cord of presymptomatic
SOD1G93Amice, where they ii) prevent astrogliosis and microglial
activation and, finally, iii) delay ALS-related decrease in the number of
motoneurons, thus resulting in iv) an amelioration of the motor
Since hMSC injections in the cisterna magna did not obtain hMSCs
migration into the spinal cord, we injected hMSCs intraparenchymally
intothe lumbar spinal cord. Labelling with bisbenzimide allowed their
localization, even several months after injection. We never observed
macrophages or glial cells with bisbenzimide-positive inclusions, nor
large bisbenzimide-positive motoneurons, as it could be hypothesized
in case of fusionwith host progenitors or mature cells (Alvarez-Dolado
et al., 2003; Kozorovitskiy and Gould, 2003; Horvath et al., 2006).
Diffusion and long term survival of transplanted hMSCs
hMSCs display a limited proliferation in vivo: we never found
dividing bisbenzimide-positive nuclei. Moreover, we observed a
limited diffusion of hMSCs, in agreement with previous reports in
which MSCs engraftment was less efficient in the adult than in the
neonatal central nervous system, since they express neural adhesion
proteins and receptors which regulate neural cell migration into the
brain (Phinney et al., 2006). hMSCs transplanted into the lumbar
spinal cord survive for long periods (more than 10 weeks), without
immunosuppression (in agreement with Liu et al., 2006b), and diffuse
1–2 mm from the injection site. Several bisbenzimide-positive nuclei
were found close to motoneurons, where hMSCs can deliver trophic
and immunomodulatory factors. Allotransplantation seems to
improve MSC survival without immunosuppression (Xu et al., 2006).
Differentiation of hMSCs into neural cells
hMSCs under specific culture conditions can express neural
markers normally expressed at various stages of neural development,
such as GFAP, Nestin, Tuj-1, Tyrosine Hydroxylase and MAP2 (Wood-
bury et al., 2000; Black and Woodbury, 2001; Deng et al., 2001;
Kohyama et al., 2001; Minguell et al., 2001; Kim et al., 2002; Tondreau
et al., 2004; Mareschi et al., 2006). At RT-PCR, undifferentiated hMSCs
expressed mRNA for MAP-2, neuron-specific enolase and neurofila-
ment-M (Mareschi et al., 2006), Nestin and βIII tubulin (Tondreau et
al., 2004). Moreover, electrophysiology on differentiated hMSCs found
K+channels usually expressed in cerebral cortex (Mareschi et al.,
2006). Our experiments in vivo, in agreement with others
(Brazelton et al., 2000; Sanchez-Ramos et al., 2000; Munoz-Elias
et al., 2004; Bonilla et al., 2005; Xu et al., 2006), seem to support
a neural differentiation of hMSCs, as shown by GFAP and MAP2
On the other hand, the morphological changes and the increased
immunoreactivity for neural markers following chemical induction
might be consequent to cellular toxicity and related cytoskeletal
changes (Lu et al., 2004; Neuhuber et al., 2004; Bertani et al., 2005,
Kim et al., 2006). Massive MSC death has been described with transfer
of donor labels into host macrophages, glial cells and neurons (Coyne
et al., 2006). In addition, BMCs do not differentiate into astrocytes
(Wehner et al., 2003). Therefore, neural differentiation has been
questioned (Castro et al., 2002; Vallières and Sawchenko, 2003).
MSCs are undifferentiated cells which express at very low levels
markers for different cell lines and can be induced to increase the
expression of some markers (Minguell et al., 2005; Blondheim et al.,
2006), which could also explain our results in vivo.
We never found CD11b-positive bisbenzimide-positive cells,
therefore we tend to exclude a hMSC differentiation into microglia,
as supported by the high selectivity of the process of cell isolation and
For the above reasons, we support the idea that MSC transplanta-
tion more than replacing lost neurons increases neuron survival and
prevents astrogliosis and microglia activation (see below) (Lepore and
Maragakis, 2007; Nayak et al., 2007).
ALS is more frequent and rapidly progressive in males than in
females (Mahoney et al., 2004; Suzuki et al., 2007). Estrogen
represents a neuroprotectant in both the adult and the aging brain,
both in vitro and in vivo (Suzuki et al., 2006).
Therefore, we groupedthe experimental animalsaccording totheir
sex, and found significant differences in survival, motor performance
and histological parameters. In sham-operated groups the males died
long before females and following transplantation had consistently
fewer motoneurons than age-matched females, and a higher density
of CD11b- of GFAP-positive profiles. This led to important decrease in
motor performance in males. On the other hand, in male mice, the
disease often brought the animals to death before the age we decided
to examine their histology. In females the progression of the disease
was slower, such that histological changes were present in the
absence of motor deficits. Therefore, we studied the effect of hMSC
transplantation on motor performance and on survival in males, and
that on histological parameters in females. Interestingly, we found a
higher percentage of the reactive astrogliosis for the transplanted
males compared to the transplanted females and a reduction of GFAP
expression for the transplanted males compared to sham-operated
Effect of hMSCs on the neuroinflammation
Neuroinflammation is a major event in ALS (Obal et al., 2001;
McGeer and McGeer, 2002). Neuroinflammation is sustained by the
interaction of microglia, neurons and macroglia (astrocytes and
oligodendrocytes): astrocytes are both the target and the source of
neuroinflammation, sinceastrocytesstimulated bymediatorsreleased
from microglia down-regulate the expression of neurotrophic factors
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405
and release additional inflammatory mediators, which in turn further
activate microglia (Weydt and Moller, 2005; Borchelt, 2006). Reactive
astrocytosis is present in the presymptomatic stage and gradually
increases to end-stage disease (Feeney et al., 2001). Microglia
participates in the pathogenesis of neurological disorders (Weydt
and Moller, 2005). Experimental evidence from transgenic animals
implicates microglia in the pathogenesis of ALS. Several studies
demonstrated that the expression of proinflammatory mediators is an
early event in murine ALS, even preceding the development of clinical
signs. Nitric oxide, a gaseous neurotransmitters involved in both
neuroprotection and excitotoxicity, produced in both glia and
neurons, is upregulated in the spinal cord of SOD1G93Amice (Phul et
al., 2000; Urushitami and Shimohama, 2001).
We observed reactive astrogliosis and microglial activation in the
SOD1G93Amice, and that hMSC transplantation modulates neuroin-
flammation by reducing microglial activation and astrocytosis as
shown by quantification in transplanted SOD1G93Acompared to sham-
operated mice. The immunosuppressive role of hMSCs, in addition to
the neuroprotective one, is confirmed by their efficacy in treating
multiple sclerosis (Uccelli et al., 2006). A role in preventing
astrogliosis and microglial activation has been hypothesized also for
neural stem cells (reviewed in Christou et al., 2007).
Neuroprotective effect of MSC transplantation
MSCs can be considered as trophic mediators (Caplan and Dennis,
2006) via the production of an assortment of cytokines, of the
angiogenetic VEGF, of the prosurvival gene Akt1. MSCs can stimulate
neural stem cells (Lou et al., 2003). MSCs can be genetically modified
to produce and deliver neurotrophic factors in loco (Hamada et al.,
2005; Kurozumi et al., 2005), or angiogenic factor (Liu et al., 2006a)
respectively to protect neurons and favor revascularization in
neurodegenerative diseases (McMahon et al., 2006). Subclones of
MSCs already produce brain-derived neurotrophic factor and β-nerve
growth factor (Crigler et al., 2006).
We have shown that following hMSC transplantation the progres-
sion of motoneuron cell death is consistently (35%) delayed in
transplanted SOD1G93Afemales compared to the sham-operated.
Unfortunately, SOD1G93Asham-operated males died long before the
sacrifice date to count motoneurons: nevertheless, counts of moto-
neurons in these mice gave a significant difference if compared to data
obtained in transplanted males. Moreover, the transplanted males
displayed a motoneuron loss similar to the sham-operated females
and more consistent than in the transplanted females, confirming the
more severe disease course in the SOD1G93Amales. Trophic factors
produced by MSCs such as VEGF (Caplan and Dennis, 2006) or BDNF
(Crigler et al., 2006) can support motoneuron survival both diffusing
at distance and by local interaction with motoneurons, since we have
observed bisbenzimide-positive nuclei close to motoneurons, where
they can exert their paracrine function (Xu et al., 2007). In addition,
transplanted hMSCs can provide motoneurons with wild type SOD.
Similar results were reported by other authors using neural stem cells
which secrete GDNF (reviewed in Christou et al., 2007; Hedlund et al.,
Effects of MSC transplantation on motor behavior
From the 5th month of age SOD1G93Amice display impaired
exploratory activity and motor coordination (Lalonde et al., 2005),
followed by asymmetric hind limb weakness, spasticity and atrophy,
exacerbated by high intensity endurance exercise training in males
(Mahoney et al., 2004). We have shown that, in males, motor behavior
is dramatically impaired from 32 weeks of age, significantly delayed
by hMSC transplantation. All parameters here considered, scoring of
motor deficits, performance on the Rotarod task and PaGE test were
able to differentiate between treated and untreated male mice (Weydt
et al., 2003). hMSC transplantation had no effects on motor behavior
in female at the age here considered, when sham-operated females
also had normal motor performance.
Our study clearly supports stem cell therapy as a promising tool in
the treatment of neurodegenerative diseases. In agreement with
others, it suggests that the intraspinal transplantation is the most
efficient way of delivering MSCs (similarly for hNT neurons,
Garbuzova-Davis et al., 2001). Moreover, hMSCs can be transplanted
in the absence of immunosuppression, probably due to their
immunomodulatory capability itself and to the use of MSCs from
other species. MSCs can be considered as biologic minipumps
migrating close to motoneurons affected by the disease, delivering
trophic factors andimmunomodulatorymolecules. MSC therapycould
be exploited by inserting genes coding for specific neurotrophic
factors or immunomodulatory molecules. The low level of prolifera-
tion represents an advantage on other stem cells, since we never
observed the formation of teratomas.
In addition, whereas the use of neural stem cells requires
heterologous transplantation and embryonic donors, and further
information is needed on the mechanisms leading to cell differentia-
tion in order to provide cell replacement (Christou et al., 2007;
Hedlundet al., 2007), MSCscan be collected fromthe patient itself and
have been used since a long time in bone marrow transplantation thus
reducing concerns about their safety.
One limitation of this study is the use of human MSCs in a rodent:
of course, signaling molecules, cytokines, and factors might have
receptorsand signaling cascades.On the otherhand,we neededtotest
safety of hMSCs on an animal model before performing tests in
humans. In addition, the major issue in this therapeutic protocol
consists in the way of administration, a rather invasive approach
including laminectomy and opening of the meninges in patients
which are already affected by a devastating disease. Nevertheless,
clinical trials have been authorized and some patients have been
intraspinally administered with hMSCs with very few minor side
effects (Mazzini et al., 2006). Experimenting intravenous delivery,
eventually after engineering MSCs with neural adhesion genes to
exploit their extravasation and intraparenchimal migration into the
nervous system, could allow a less invasive approach.
Supported by grants to F. Fagioli, E. Madon and A. Vercelli from
Compagnia di San Paolo, Italian Ministry of Health and Vialli-Mauro
Foundation. We are grateful to Dr. Ferdinando Rossi for the critical
reading of the manuscript.
Aggarwal, S., Pittenger, M.F., 2005. Human mesenchymal stemcells modulate allogeneic
immune cell response. Blood 105, 1815–1822.
Alvarez-Dolado, M., Pardal, R., Garcia-Verdugo, J.M., Fike, J.R., Lee, H.O., Pfeffer, K.,
Lois, C., Morrison, S.J., Alvarez-Buylla, A., 2003. Fusion of bone-marrow-derived
cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425,
Bertani, N., Malatesta, P., Volpi, G., Sonego, P., Perris, R., 2005. Neurogenic potential of
human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse
video and microarray. J. Cell Sci. 118, 3925–3936.
Black, I.B., Woodbury, D., 2001. Adult rat and human bone marrow stromal stem cells
differentiate into neurons. Blood Cells Mol. Dis. 27, 632–636.
Blondheim, N.R., Levy, Y.S., Ben-Zur, T., Burshtein, A., Cherlow, T., Kan, I., Barzilai, R.,
Bahat-Stromza, M., Barhum, Y., Bulvik, S., Melamed, E., Offen, D., 2006. Human
mesenchymal stem cells express neural genes, suggesting a neural predisposition.
Stem Cells Dev. 15, 141–164.
Bonilla, S., Silva, A., Valdes, L., Geijo, E., Garcia-Verdugo, J.M., Martinez, S., 2005.
Functional neural stem cells derived from adult bone marrow. Neuroscience 133,
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405
Borchelt, D.R., 2006. Amyotrophic lateral sclerosis—are microglia killing motor
neurons? N. Engl. J. Med. 12, 1611–1613.
Brazelton, T.R., Rossi, F.M.V., Keshet, G.I., Blau, H.M., 2000. From marrow to brain:
expression of neuronal phenotypes in adult mice. Science 290, 1775–1779.
Caplan, A.I., Dennis, J.E., 2006. Mesenchymal stem cells as trophic mediators. J. Cell.
Biochem. 98, 1076–1084.
Carri, M.T., Grignaschi, G., Bendotti, C., 2006. Targets in ALS: designing multidrug
therapies. Trends Pharmacol. Sci. 27, 267–273.
Castro, R.F., Jackson, K.A., Goodell, M.A., Robertson, C.S., Liu, H., Shine, H.D., 2002. Failure
of bone marrow cells to transdifferentiate into neural cells in vivo. Science 297,
Christou, Y.A., Moore, H.D., Shaw, P.J., Monk, P.N., 2007. Embryonic stem cells and
prospects for their use in regenerative medicine approaches to motor neuron
disease. Neuropathol. Appl. Neurobiol. 33, 485–498.
Ciavarro, G.L., Calvaresi, N., Botturi, A., Bendotti, C., Andreoni, G., Pedotti, A., 2003. The
densitometric physical fractionator for counting neuronal populations: application
to a mouse model of familial amyotrophic lateral sclerosis. J. Neurosci. Meth. 129,
Clement, A.M., Nguyen, M.D., Roberts, E.A., Garcia, M.L., Boillee, S., Rule, M., McMahon,
A.P., Doucette, W., Siwek, D., Ferrante, R.J., Brown, R.H., Julien, J.P., Goldstein, L.S.,
Cleveland, D.W., 2003. Wild-type nonneuronal cells extend survival of SOD1
mutant motor neurons in ALS mice. Science 302, 113–117.
Corti, S., Locatelli, F., Donadoni, C., Guglieri, M., Papadimitriou, D., Strazzer, S., Del Bo, R.,
Comi, G.P., 2004a. Wild-type bone marrowcells ameliorate the phenotype of SOD1-
G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain 127,
Corti, S., Locatelli, F., Papadimitriou, D., Strazzer, S., Comi, G.P., 2004b. Somatic stem cell
research for neural repair: current evidence and emerging perspectives. J. Cell Mol.
Med. 8, 329–337.
Corti, S., Locatelli, F., Papadimitriou, D., Del Bo, R., Nizzardo, M., Nardini, M., Donadoni,
C., Salani, S., Fortunato, F., Strazzer, S., Bresolin, N., Comi, G.P., 2007. Neural stem
cells LewisX+CXCR4+ modify disease progression in an amyotrophic lateral
sclerosis model. Brain, 130, 1289–1305.
Coyne, T.M., Marcus, A.J., Woodbury, D., Black, I.B., 2006. Marrow stromal cells
transplanted to the adult brain are rejected by an inflammatory response and
transfer donor labels to host neurons and glia. Stem Cells 24, 2483–2492.
Crigler, L., Robey, R.C., Asawachaicharn, A., Gaupp, D., Phinney, D.G., 2006. Human
mesenchymal stem cell subpopulations express a variety of neuro-regulatory
molecules and promote neuronal cell survival. Exp. Neurol. 198, 54–64.
Deng, W., Obrocka, M., Fischer, I., Prockop, D.J., 2001. In vitro differentiation of human
marrow stromal cells into early progenitors of neural cells by conditions that
increase intracellular cyclic AMP. Biochem Biophys Res. Commun. 282, 148–152.
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P.D., Matteucci, P.,
Grisanti, S., Gianni, A.M., 2002. Human bone marrow stromal cells suppress T-
lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.
Blood 99, 3838–3843.
Doble, A., Kennel, P., 2000. Animal models of amyotrophic lateral sclerosis. Amyotroph.
Lateral Scler. Other Motor Neuron Dis. 1, 301–312.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans,
R., Keating, A., Prockop, D.J., Horwitz, E., 2006. Minimal criteria for defining
multipotent mesenchymal stromal cells. Cytotherapy 8, 315–317.
Feeney,S.J., McKelvie,P.A., Austin,L., Jean-Francois,M.J., Kapsa, R.,Tombs,S.M., Byrne, E.,
2001. Presymptomatic motor neuron loss and reactive astrocytosis in the SOD1
mouse model of amyotrophic lateral sclerosis. Muscle Nerve 24, 1510–1519.
Ferrero, I.,Mazzini,L.,Rustichelli, D.,Gunetti, M.,Mareschi,K.,Testa,L.,Naselli,N., Oggioni,
G.D., Fagioli, F., 2008. Bone marrow mesenchymal stem cells from healthy donors and
sporadic amyotrophic lateral sclerosis patients. Cell Transplant.17, 255–266.
Garbuzova-Davis, S., Willing, A.E., Milliken, M., Saporta, S., Sowerby, B., Cahill, D.W.,
Sanberg, P.R., 2001. Intraspinal implantation of hNT neurons into SOD1 mice with
apparent motor deficit. Amyotroph. Lateral Scler. Other Motor Neuron Dis. 2,
Govoni, V., Granieri, E., Capone, J., Manconi, M., Casetta, I., 2003. Incidence of
amyotrophic lateral sclerosis in the local health district of Ferrara, Italy, 1964–
1998. Neuroepidemiology 22, 229–234.
Hamada, H., Kobune, M., Nakamura, K., Kawano, Y., Kato, K., Honmou, O., Houkin, K.,
Hermann, A., Gastl, R., Liebau, S., Popa, M.O., Fiedler, J., Boehm, B.O., Maisel, M., Lerche,
cells from adult human bone marrow stromal cells. J. Cell Sci. 117, 4411–4422.
Hedlund, E., Hefferan, M.P., Marsala, M., Isacson, O., 2007. Cell therapy and stem cells in
animal models of motor neuron disorders. Eur. J. Neurosci. 26, 1721–1737.
Horvath, E.M., Lacza, Z., Csordas, A., Szabo, C., Kollai, M., Busija, D.W., 2006. Graft derived
cells with double nuclei in the penumbral region of experimental brain trauma.
Neurosci. Lett. 396, 182–186.
Kim, B.J., Seo, J.H., Bubien, J.K., Oh, Y.S., 2002. Differentiation of adult bone marrow stem
cells into neuroprogenitor cells in vitro. Neuroreport 13, 1185–1188.
Kim, S., Honmou, O., Kato, K., Nonaka, T., Houkin, K., Hamada, H., Kocsis, J.D., 2006.
Neural differentiation potential of peripheral blood- and bone-marrow-derived
precursor cells. Brain Res. 1123, 27–33.
Kohyama, J., Abe, H., Shimazaki, T., 2001. Brain from bone: efficient metadifferentiation
of marrow stroma-derived mature osteoblasts to neurons with Noggin or a
demethylating agent. Differentiation 68, 235–244.
Kozorovitskiy, Y., Gould, E., 2003. Stem cell fusion in the brain. Nat. Cell Biol. 5, 952–954.
Kurozumi, K., Nakamura, K., Tamiya, T., Kawano, Y., Ishii, K., Kobune, M., Hirai, S., Uchida,
H., Sasaki, K., Ito, Y., Kato, K., Honmou, O., Houkin, K., Date, I., Hamada, H., 2005.
Mesenchymal stem cells that produce neurotrophic factors reduce ischemic
damage in the rat middle cerebral artery occlusion model. Mol. Ther. 11, 96–104.
Lalonde, R.,Le Pecheur, M., Strazielle,C., London, J., 2005. Exploratoryactivityand motor
coordination inwild-type SOD1/SOD1 transgenic mice. Brain Res. Bull. 66,155–162.
Le Blanc, K., 2003. Immunomodulatory effects of fetal and adult mesenchymal stem
cells. Cytotherapy. 5, 485–489.
Lepore, A.C., Maragakis, N.J., 2007. Targeted stem cell transplantation strategies in ALS.
Neurochem. Int. 50, 966–975.
Liu, H., Honmou, O., Harada,K., Nakamura,K., Houkin, K., Hamada, H.,Kocsis,J.D., 2006a.
Neuroprotection by PlGF gene-modified human mesenchymal stem cells after
cerebral ischaemia. Brain 129, 2734–2745.
Liu, L., Sun, Z., Chen, B., Han, Q., Liao, L., Jia, M., Cao, Y., Ma, J., Sun, Q., Guo, M., Liu, Z., Ai,
H., Zhao, R.C., 2006b. Ex vivo expansion and in vivo infusion of bone marrow-
derived Flk-1_CD31_CD34_ mesenchymal stem cells: feasibility and safety from
monkey to human. Stem Cells Dev. 15, 349–357.
Lou, S., Gu, P., Chen, F., He, C., Wang, M., Lu, C., 2003. The effect of bone marrow stromal
cells on neuronal differentiation of mesencephalic neural stem cells in Sprague–
Dawley rats. Brain Res. 968, 114–121.
differentiation, transdifferentiation, or artifact? J. Neurosci. Res. 77,174–191.
Mahoney, D.J., Rodriguez, C., Devries, M., Yasuda, N., Tarnopolsky, M.A., 2004. Effects of
high-intensity endurance exercise training in the G93A mouse model of
amyotrophic lateral sclerosis. Muscle Nerve 29, 656–662.
Mareschi, K., Biasin, E., Piacibello, W., Aglietta, M., Madon, E., Fagioli, F., 2001. Isolation of
human mesenchymal stem cells: bone marrow versus umbilical cord blood.
Haematologica 86, 1099–1100.
Mareschi, K., Novara, M., Rustichelli, D., Ferrero, I., Guido, D., Carbone, E., Medico, E.,
Madon, E., Vercelli, A., Fagioli, F., 2006. Neural differentiation of human
mesenchymal stem cells: evidence for expression of neural markers and eag K+
channel types. Exp. Hematol. 34, 1563–1572.
Mazzini, L., Fagioli, F., Boccaletti, R., Mareschi, K., Oliveri, G., Olivieri, C., Pastore, I.,
Marasso, R., Madon, E., 2003. Stem cell therapy in amyotrophic lateral sclerosis: a
methodological approach in humans. Amyotroph. Lateral Scler. Other Motor
Neuron Disord. 4, 158–161.
Mazzini, L., Fagioli, F., Boccaletti, R., 2004. Stem-cell therapy in amyotrophic lateral
sclerosis. Lancet 364, 1936–1937.
Mazzini, L., Mareschi, K., Ferrero, I., Vassallo, E., Oliveri, G., Boccaletti, R., Testa, L., Livigni,
S., Fagioli, F., 2006. Autologous mesenchymal stem cells: clinical applications in
amyotrophic lateral sclerosis. Neurol. Res. 28, 523–526.
McGeer, P.L., McGeer, E.G., 2002. Inflammatory processes in amyotrophic lateral
sclerosis. Muscle Nerve 26, 459–470.
McMahon, J.M., Conroy, S., Lyons, M., Greiser, U., O'Shea, C., Strappe, P., Howard, L.,
Murphy, M., Barry, F., O'Brien, T., 2006. Gene transfer into rat mesenchymal stem
cells: a comparative study of viral and nonviral vectors. Stem Cells Dev. 15, 87–96.
Minguell, J.J., Erices, A., Conget, P., 2001. Mesenchymal stem cells. Exp. Biol. Med. 226,
Minguell, J.J., Fierro, F.A., Epunan, M.J., Erices, A.A., Sierralta, W.D., 2005. Nonstimulated
human uncommitted mesenchymal stem cells express cell markers of mesench-
ymal and neural lineages. Stem Cells Dev. 14, 408–414.
Munoz-Elias, G., Marcus, A.J., Coyne, T.M., Woodbury, D., Black, I.B., 2004. Adult bone
marrow stromal cells in the embryonic brain: engraftment, migration, differentia-
tion, and long-term survival. J. Neurosci. 24, 4585–4595.
Nagano, I., Ilieva, H., Shiote, M., Murakami, T., Yokoyama, M., Shoji, M., Abe, K., 2005.
Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a
mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 235, 61–68.
Nayak, M.S., Kim, Y.-S., Goldman, M., Keirstead, H.S., Kerr, D.A., 2007. Cellular therapies
in motor neuron diseases. Biochim. Biophys. Acta 1762, 1128–1138.
Neuhuber, B., Gallo, G., Howard, L., Kostura, L., Mackay, A., Fischer, I., 2004. Reevaluation
of in vitro differentiation protocols for bone marrow stromal cells: disruption of
actin cytoskeleton induces rapid morphological changes and mimics neuronal
phenotype. J. Neurosci. Res. 77, 192–204.
Obal, I., Jakab, J.S., Siklos, L., Engelhardt, J.I., 2001. Recruitment of activated microglia
cells in the spinal cord of mice by ALS IgG. Neuroreport 12, 2449–2452.
Phinney, D.G., Baddoo, M., Dutreil, M., Gaupp, D., Tzu Lai, W., Isakova, I.A., 2006. Murine
mesenchymal stem cells transplanted to the central nervous system of neonatal
versus adult mice exhibit distinct engraftment kinetics and express receptors that
guide neuronal cell migration. Stem Cells Dev. 15, 437–447.
Phul, R.K., Shaw, P.J., Ince, P.G., Smith, M.E., 2000. Expression of nitric oxide synthase
isoforms in spinal cord in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler.
Other Motor Neuron Dis. 1, 259–267.
Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., Hentati, A., Donaldson,
D., Goto, J., O'Regan, J.P., Deng, H.X., et al., 1993. Mutations in Cu/Zn superoxide
dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature
Rowland, L.P.,1998. Diagnosis of amyotrophic lateral sclerosis. J. Neurol. Sci.160 (Suppl.
Sanchez-Ramos, J., Song, S., Cardozo-Pelaez, F., Hazzi, C., Stedeford, T., Willing, A.,
Freeman, T.B., Saporta, S., Janssen, W., Patel, N., Cooper, D.R., Sanberg, P.R., 2000.
Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp. Neurol.
Selverstone Valentine, J., Doucette, P.A., Zittin Potter, S., 2005. Copper–zinc superoxide
dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem. 74, 563–593.
Silani, V., Cova, L., Corbo, M., Ciammola, A., Polli, E., 2004. Stem-cell therapy for
amyotrophic lateral sclerosis. Lancet 364, 200–202.
Storkebaum, E., Lambrechts, D., Dewerchin, M., Moreno-Murciano, M.P., Appelmans, S.,
Oh, H., Van Damme, P., Rutten, B., Man, W.Y., De Mol, M., Wyns, S., Manka, D.,
Vermeulen, K., Van Den Bosch, L., Mertens, N., Schmitz, C., Robberecht, W., Conway,
E.M., Collen, D., Moons, L., Carmeliet, P., 2005. Treatment of motoneuron
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405
degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.
Nature Neurosci. 8, 85–92.
Strong, M., 2003. The basic aspects of therapeutics in amyotrophic lateral sclerosis.
Pharmacol. Ther. 98, 379–414.
Suzuki, S., Brown, C.M., Wise, P.M., 2006. Mechanisms of neuroprotection by estrogen.
Endocrine 29, 209–215.
Suzuki, M., Tork, C., Shelley, B., McHugh, J., Wallace, K., Klein, S.M., Lindstrom, M.J.,
Svendsen, C.N., 2007. Sexual dimorphism in disease onset and progression of a rat
model of ALS. Amyotroph. Lateral Scler. 8, 20–25.
Svendsen, C.N., Langston, J.W., 2004. Stem cells for Parkinson disease and ALS:
replacement or protection? Nature Med. 10, 224–225.
Tondreau, T., Lagneaux, L., Dejeneffe, M., Massy, M., Mortier, C., Delforge, A., Bron, D.,
2004. Bone marrow derived mesenchymal stem cells already express specific
neural proteins before any differentiation. Differentiation 72, 319–326.
Uccelli, A., Zappia, E., Benvenuto, F., Frassoni, F., Mancardi, G., 2006. Stem cells in
inflammatory demyelinating disorders: a dual role for immunosuppression and
neuroprotection. Expert Opin. Biol. Ther. 6, 17–22.
Urushitani, M., Shimohama, S., 2001. The role of nitric oxide in amyotrophic lateral
sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Dis. 2, 71–81.
Vallières, L., Sawchenko, P.E., 2003. Bone marrow-derived cells that populate the adult
mouse brain preserve their hematopoietic identity. J. Neurosci. 23, 5197–5207.
Wang, Y., Ou Mao, X., Xie, L., Banwait, S., Marti, H.H., Greenberg, D.A., Jin, K., 2007.
Vascular endothelial growth factor overexpression delays neurodegeneration
and prolongs survival in amyotrophic lateral sclerosis mice. J. Neurosci. 27,
Wehner, T., Bontert, M., Eyupoglu, I., Prass, K., Prinz, M., Klett, F.F., Heinze, M.,
Bechmann, I., Nitsch, R., Kirchhoff, F., Kettenmann, H., Dirnagl, U., Priller, J., 2003.
Bone marrow-derived cells expressing green fluorescent protein under the control
of the glial fibrillary acidic protein promoter do not differentiate into astrocytes in
vitro and in vivo. J. Neurosci. 23, 5004–5011.
West, M.J., Slomianka, L., Gundersen, H.J.,1991. Unbiased stereological estimation of the
total number of neurons in the subdivisions of the rat hippocampus using the
optical fractionator. Anat. Rec. 231, 482–497.
Weydt, P., Hongso, Y., Kliot, M., Moller, T., 2003. Assessing disease onset and progression
in the SOD1 mouse model of ALS. Neuroreport 14, 1051–1054.
Weydt, P., Moller, T., 2005. Neuroinflammation in the pathogenesis of amyotrophic
lateral sclerosis. Neuroreport 16, 527–531.
Woodbury, D., Schwarz, E.J., Prockop, D.J., Black, I.B., 2000. Adult rat and human bone
marrow stromal cells differentiate into neurons. J. Neurosci. Res. 61, 364–370.
Xu, L., Yan, J., Chen, D., Welsh, A.M., Hazel, T., Johe, K., Hatfield, G., Koliatsos, V.E., 2006.
Human neural stem cell grafts ameliorate motor neuron disease in SOD-1
transgenic rats. Transplantation 82, 865–875.
A. Vercelli et al. / Neurobiology of Disease 31 (2008) 395–405